A novel therapy designed to clear toxic clumps of a protein thought to be responsible for Parkinson’s disease has shown promise in early clinical trials.
Produced by the US biotechnology company Vaxxinity, the immunotherapy candidate codenamed UB-312 is the first treatment shown to be capable of reducing concentrations of alpha-synuclein (α-syn) in cerebrospinal fluid, marking a significant step forward in slowing – or even halting – the disorder’s progress.
Though the results of the trial are yet to be published and peer reviewed, reports from company officials are optimistic, suggesting they’re onto something big.
"Analysis of the spinal fluid of those given UB-312 revealed a 20 percent drop in their usual α-syn aggregate levels, compared with a 3 percent decline in those who received a placebo."#Parkinsons#longcovid https://t.co/BAdtKw2Dj8
— Troy Roach (@Canal1point5) March 12, 2024